Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' request for sensitive information.
This rejection became public after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson has since stated that the US was seeking health data for research and profit while was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more talks to find a deal suitable to all parties so the nation's vital HIV treatment initiative can continue.
Wider Context
This development comes after a comparable case in Kenya, where a court halted a similar deal with the US following legal challenges were raised about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
According to statements, 16 nations in Africa have so far signed these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Effectively, our country would supply the basic resources for medical research without any certainty that the resulting innovations would be accessible to our population should a future health crisis arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of bilateral deals were disrupting frameworks previously established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This framework is intended to guarantee that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," he added.
"We are open to continued dialogue with our American counterparts on how future co-operation might be designed in a manner that honours the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but recommended that talks should continue considering much of the nation's Aids initiatives relied on foreign aid.
"If technical issues arise, including those involving data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," it commented.
This impasse emphasises the complex debate between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.